CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) announced today that Scott Canute, the former manufacturing head at Eli Lilly & Company and a respected leader in the field, joined the company as President of Global Manufacturing and Corporate Operations. In this position, Mr. Canute will oversee the production of a diverse range of products manufactured at 17 sites around the world.
“Scott Canute is among the very top people in the pharmaceutical manufacturing field,” said Henri A. Termeer, Genzyme’s chairman and chief executive officer. “He is widely respected for transforming manufacturing operations at Lilly and establishing its programs as a standard for the industry. His experience will accelerate efforts to strengthen our manufacturing sites, and consistently meet world-class standards.”
“I am very excited to be joining Genzyme, which clearly has such a strong history of innovation and excellence,” said Scott Canute. “I look forward to helping the company achieve the manufacturing capabilities that are necessary to fully serve the patients that depend on our products - both now and in the future.”
Last month, Genzyme also announced that Ron Branning, a leader in the field of product quality, joined the company as Senior Vice President of Global Product Quality. The hiring of new leadership in Manufacturing and Quality is part of Genzyme’s comprehensive plan to strengthen its global manufacturing operations.
Mr. Canute held progressively responsible positions at Lilly, ultimately becoming President of Global Manufacturing Operations. In this role, he directed all manufacturing and supply chain activities for the company’s operations, which spanned 24 global manufacturing sites and more than 80 contract manufacturing operations. Mr. Canute oversaw operations that included more than 14,000 employees, and that supplied product to more than 140 countries. He also has experience with a variety of technologies, including biologics, small and large molecules, and devices.
During his 25-year career, he has resolved significant challenges, including FDA warning letters and 483 post-inspection letters. He has also managed multiple product launches and the development of new manufacturing sites. During his tenure, Lilly’s manufacturing training programs became models in the industry.
Mr. Canute holds a degree in chemical engineering from the University of Michigan, and a masters in business administration from Harvard Business School. He was also a National Association of Manufacturers board member. In 2007, Mr. Canute left Lilly to pursue educational interests in business leadership and ethics.
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.
With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.
Genzyme® is a registered trademark of Genzyme Corporation. All rights reserved.
Genzyme’s press releases and other company information are available at www.genzyme.com and by calling Genzyme’s investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6165444&lang=en